Chaya Moskowitz, PhD

Attending Biostatistician

Chaya Moskowitz, PhD

Attending Biostatistician
Chaya Moskowitz, Attending  Biostatistician


University of Washington

Current Research Interests

Dr. Moskowitz’s research focuses on studying the late effects of cancer therapy in childhood, adolescent, and young adult cancer survivors and on evaluating medical imaging tests used for screening, diagnosis, and prediction. She collaborates with investigators from a variety of disciplines engaged in research in cancer survivorship, radiology, and exercise oncology, both within MSK as well as throughout the international research community. She has served on Editorial Boards for leading oncology journals, Journal of Clinical Oncology and Journal of the National Cancer Institute, and serves as a Statistical Reviewer for the journals Radiology and Journal of the American Medical Association.


Selected peer-reviewed publications:

  1. Moskowitz CS, Jia X, Schwartz LH, Gönen M. A simulation study to evaluate the impact of the number of lesions measured on response assessment. Eur J Cancer. 2009 Jan; 45(2): 300-310.
  2. Moskowitz CS, Chou JF, Wolden SL, Bernstein JL, Malhotra J, Friedman DN, Mubdi NZ, Leisenring WM, Stovall M, Hammond S, Smith SA, Henderson TO, Boice JD, Hudson MM, Diller LR, Bhatia S, Kenney LB, Neglia JP, Begg CB, Robison LL, Oeffinger KC. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014 Jul 20;32(21):2217-23.
  3. Moskowitz CS, Ronckers CM, Chou JF, Smith SA, Friedman DN, Barnea D, Kok JL, de Vries S, Wolden SL, Henderson TO, van der Pal HJH, Kremer LCM, Neglia JP, Turcotte LM, Howell RM, Arnold MA, Schaapveld M, Aleman B, Janus C, Versluys B, Leisenring W, Sklar CA, Begg CB, Pike MC, Armstrong GT, Robison LL, van Leeuwen FE, Oeffinger KC. Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts. J Clin Oncol. 2021 Sep 20;39(27):3012-3021. doi: 10.1200/JCO.20.02244. Epub 2021 May 28. PMID: 34048292.
  4. Moskowitz CS, Welch ML, Jacobs MA, Kurland BF, Simpson AL. Radiomic Analysis: Study Design, Statistical Analysis, and Other Bias Mitigation Strategies. Radiology. 2022 Aug;304(2):265-273.
  5. Henderson TO, Liu Q, Turcotte LM, Neglia JP, Leisenring W, Hodgson D, Diller L, Kenney L, Morton L, Berrington de Gonzalez A, Arnold M, Bhatia S, Howell RM, Smith SA, Robison LL, Armstrong GT, Oeffinger KC, Yasui Y, Moskowitz CS. Association of Changes in Cancer Therapy Over 3 Decades With Risk of Subsequent Breast Cancer Among Female Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study (CCSS). JAMA Oncol. 2022 Oct 13;8(12):1765-74.

Visit PubMed for a full listing of Chaya Moskowitz’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Chaya Moskowitz discloses the following relationships and financial interests:

  • Journal of the American Medical Association
    Professional Services and Activities
  • Radiological Society of North America
    Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures